MCID: SCR001
MIFTS: 40

Secretory Meningioma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Secretory Meningioma

MalaCards integrated aliases for Secretory Meningioma:

Name: Secretory Meningioma 12 54 15 17 71
Meningioma 71

Classifications:



External Ids:

Disease Ontology 12 DOID:4588
MeSH 44 D008579
NCIt 50 C4718
SNOMED-CT 67 253081009
UMLS 71 C0025286 C1384406

Summaries for Secretory Meningioma

MalaCards based summary : Secretory Meningioma, also known as meningioma, is related to spinal meningioma and signet ring cell adenocarcinoma. An important gene associated with Secretory Meningioma is MUC1 (Mucin 1, Cell Surface Associated), and among its related pathways/superpathways is Cytoskeletal Signaling. The drugs Thrombin and Tranexamic Acid have been mentioned in the context of this disorder. Affiliated tissues include pituitary, spinal cord and brain, and related phenotype is Increased proliferation.

Related Diseases for Secretory Meningioma

Diseases related to Secretory Meningioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 322)
# Related Disease Score Top Affiliating Genes
1 spinal meningioma 30.1 TRAF7 SMARCE1 SMARCB1 NF2
2 signet ring cell adenocarcinoma 29.9 MUC1 KRT7 CEACAM5
3 meningothelial meningioma 29.5 TRAF7 SMARCE1 SERPINA3 NF2
4 meningioma, familial 29.1 VIM TRAF7 SMARCE1 SMARCB1 SERPINA3 NF2
5 lymphoplasmacyte-rich meningioma 10.6
6 perineurioma 10.4 VIM MUC1
7 papillary tumor of the pineal region 10.4 VIM MUC1
8 endometrial mucinous adenocarcinoma 10.4 VIM MUC1
9 scrotum paget's disease 10.4 MUC1 KRT7
10 cutaneous leiomyosarcoma 10.4 VIM MUC1
11 gallbladder signet ring cell adenocarcinoma 10.4 MUC1 KRT7
12 pericardial mesothelioma 10.4 VIM MUC1
13 mucinous intrahepatic cholangiocarcinoma 10.4 MUC1 KRT7
14 middle ear adenoma 10.4 MUC1 KRT7
15 reticulum cell sarcoma 10.3 VIM MUC1
16 benign metastasizing leiomyoma 10.3 VIM KRT7
17 glandular cystitis 10.3 MUC1 KRT7
18 cystadenofibroma 10.3 MUC1 KRT7
19 ossifying fibromyxoid tumor 10.3 VIM MUC1
20 mucinous tubular and spindle renal cell carcinoma 10.3 MUC1 KRT7
21 polymorphous low-grade adenocarcinoma 10.3 VIM MUC1
22 biphasic synovial sarcoma 10.3 VIM MUC1
23 solid adenocarcinoma with mucin production 10.3 MUC1 KRT7
24 ovarian serous cystadenofibroma 10.3 MUC1 KRT7
25 epithelioid trophoblastic tumor 10.3 MUC1 KRT7
26 endosalpingiosis 10.3 MUC1 KRT7
27 mixed fibrolamellar hepatocellular carcinoma 10.3 MUC1 KRT7
28 dendritic cell tumor 10.3 VIM MUC1
29 intravascular papillary endothelial hyperplasia 10.3 VIM SERPINA3
30 bladder leiomyoma 10.3 VIM KRT7
31 congenital epulis 10.3 VIM SERPINA3
32 epulis 10.3 VIM SERPINA3
33 adenoid squamous cell carcinoma 10.3 VIM KRT7
34 renal pelvis carcinoma 10.3 KRT7 CEACAM7
35 malignant peritoneal mesothelioma 10.3 NF2 MUC1
36 nephrogenic adenoma 10.3 MUC1 KRT7
37 multicentric reticulohistiocytosis 10.3 VIM SERPINA3
38 syringocystadenoma papilliferum 10.3 SERPINA3 MUC1
39 adenomyoma 10.3 MUC1 KRT7
40 granulosa cell tumor of the ovary 10.3 VIM KRT7
41 odontogenic myxoma 10.3 VIM SERPINA3
42 sclerosing hemangioma 10.3 MUC1 KRT7
43 osteofibrous dysplasia 10.3 VIM MUC1
44 gastric squamous cell carcinoma 10.3 SERPINA3 KRT7
45 embryonal sarcoma 10.2 VIM SERPINA3
46 vulvar eccrine porocarcinoma 10.2 MUC1 CEACAM5
47 nodular tenosynovitis 10.2 VIM SERPINA3
48 astroblastoma 10.2 VIM MUC1
49 pediatric meningioma 10.2 TRAF7 NF2
50 acral lentiginous melanoma 10.2 VIM MUC1

Graphical network of the top 20 diseases related to Secretory Meningioma:



Diseases related to Secretory Meningioma

Symptoms & Phenotypes for Secretory Meningioma

GenomeRNAi Phenotypes related to Secretory Meningioma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 NF2 SMARCB1

Drugs & Therapeutics for Secretory Meningioma

Drugs for Secretory Meningioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 148)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Thrombin Approved, Investigational Phase 4
2
Tranexamic Acid Approved Phase 4 1197-18-8 5526
3 Fibrin Tissue Adhesive Phase 4
4 Hemostatics Phase 4
5 Coagulants Phase 4
6 Antifibrinolytic Agents Phase 4
7
Cisatracurium Approved Phase 3 96946-41-7 62887
8
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
9
Sevoflurane Approved, Vet_approved Phase 3 28523-86-6 5206
10
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 3 7487-88-9 24083
11
Propofol Approved, Investigational, Vet_approved Phase 3 2078-54-8 4943
12
Mifepristone Approved, Investigational Phase 3 84371-65-3 55245
13
Progesterone Approved, Vet_approved Phase 3 57-83-0 5994
14
Aminolevulinic acid Approved Phase 3 106-60-5 137
15 Anesthetics Phase 3
16 Antihypertensive Agents Phase 3
17 Vasoconstrictor Agents Phase 3
18 Contraceptive Agents Phase 3
19 Contraceptives, Oral Phase 3
20 Contraceptives, Postcoital Phase 3
21 Progestins Phase 3
22 Dermatologic Agents Phase 3
23 Photosensitizing Agents Phase 3
24
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
25
Hydroxyurea Approved Phase 2 127-07-1 3657
26
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
27
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
28
Copper Approved, Investigational Phase 1, Phase 2 7440-50-8 27099
29
Verapamil Approved Phase 2 52-53-9 2520
30
Mesna Approved, Investigational Phase 2 3375-50-6 598
31
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
32
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
33
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
34
carbamide peroxide Approved Phase 2 124-43-6
35
nivolumab Approved Phase 2 946414-94-4
36
Ipilimumab Approved Phase 2 477202-00-9
37
Pembrolizumab Approved Phase 2 1374853-91-4
38
Pasireotide Approved Phase 2 396091-73-9 9941444
39
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
40
Bevacizumab Approved, Investigational Phase 2 216974-75-3
41
Ifosfamide Approved Phase 2 3778-73-2 3690
42
Vatalanib Investigational Phase 2 212141-54-3 151194
43
Imidacloprid Vet_approved Phase 1, Phase 2 105827-78-9 86418
44 Cytochrome P-450 Enzyme Inhibitors Phase 2
45 Cytochrome P-450 CYP3A Inhibitors Phase 2
46 Anti-Arrhythmia Agents Phase 2
47 interferons Phase 2
48 Interferon-alpha Phase 2
49 Interferon alpha-2 Phase 2
50 Iron-Dextran Complex Phase 2

Interventional clinical trials:

(show top 50) (show all 143)
# Name Status NCT ID Phase Drugs
1 Neurocognitive Outcome Assessment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. Unknown status NCT03190122 Phase 4
2 Dissection of the Outer Layer of the Lateral Wall of the Cavernous Sinus Decreases Bleeding as Compared to Direct Tumor Attack in Middle Fossa Meningiomas: A Randomized Controlled Trial Unknown status NCT02863484 Phase 4
3 A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Standard of Care as an Adjunct to Hemostasis in Elective Brain Tumor Surgery Completed NCT02034799 Phase 4
4 Effect of Tranexamic Acid Infusion to Reduce Intraoperative Blood Loss in Large Meningioma: A Prospective Randomized Double-blind Control Study Not yet recruiting NCT04386642 Phase 4 Tranexamic acid;Placebo
5 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
6 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
7 The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal Completed NCT03558516 Phase 3 Magnesium group;Normal saline group
8 Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone In The Treatment of Unresectable Meningioma Completed NCT03015701 Phase 3 Mifepristone
9 Prospective Study Of Patients With Recurrent Or Incomplete Excised Benign Intercranial Meningiomas For The Evaluation Of Treatment Result With Combined Proton And Photon Irradiation To Doses 55.8 Or 63.0 CGE Completed NCT02947984 Phase 3
10 A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Newly Diagnosed or Recurrent Meningiomas Recruiting NCT04305470 Phase 3 Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)
11 Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma Recruiting NCT03180268 Phase 3
12 Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study Terminated NCT00104936 Phase 3
13 Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma Unknown status NCT00006119 Phase 2 hydroxyurea
14 Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas. Unknown status NCT02333565 Phase 2 Everolimus;Octreotide
15 IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study Unknown status NCT00904735 Phase 2 hydroxyurea;imatinib mesylate
16 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Completed NCT00589784 Phase 2 Sunitinib
17 Phase II Study to Evaluate the Efficacy of Recombinant Interferon-Alpha in the Treatment of Recurrent Unresectable Meningiomas and Malignant Meningiomas Completed NCT00002965 Phase 2
18 Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma Completed NCT00045734 Phase 2 imatinib mesylate
19 A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma Completed NCT00354913 Phase 2 hydroxyurea;imatinib mesylate
20 Phase II Study of Hydroxyurea for Unresectable Meningioma Completed NCT00003590 Phase 2 hydroxyurea
21 ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs Completed NCT00025675 Phase 2 gefitinib
22 Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma Completed NCT00859040 Phase 2 SOM230C
23 Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group Completed NCT02234050 Phase 2 Trabectedin
24 Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™: A Single-centre, Open-label, Non- Randomised, Phase I-IIa Theranostic Clinical Trial Completed NCT03936426 Phase 1, Phase 2 Cu-64 SARTATE and Cu-67 SARTATE
25 Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas Completed NCT01125046 Phase 2
26 A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas Completed NCT00348790 Phase 2 vatalanib
27 Combination of Hydroxyurea and Verapamil for Refractory Meningiomas Completed NCT00706810 Phase 2 Hydroxyurea;Verapamil
28 A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas Completed NCT02831257 Phase 2 AZD2014
29 Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes Completed NCT01967823 Phase 2 Cyclophosphamide;Fludarabine;Aldesleukin
30 Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas Completed NCT00010049 Phase 1, Phase 2 imatinib mesylate
31 A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy Completed NCT00045110 Phase 1, Phase 2 erlotinib hydrochloride
32 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
33 Proton Radiation for Low Grade Gliomas Completed NCT01024907 Phase 1, Phase 2
34 A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage Completed NCT00492089 Phase 2 bevacizumab;placebo
35 Effect of Hippocampal Sparing on Neurocognitive Functions and Quality of Live in Patients Irradiated in the Neurocranial Area Recruiting NCT01849484 Phase 2
36 Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2) Recruiting NCT04374305 Phase 2 Brigatinib
37 A Phase 2 Study of Abemaciclib in Patients With Recurrent Brain Tumors Recruiting NCT03220646 Phase 2 abemaciclib;abemaciclib
38 An Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma Recruiting NCT02648997 Phase 2 Nivolumab - 240 mg;Ipilimumab - 1 mg/kg;Nivolumab - 480 mg;Nivolumab - 3 mg/kg
39 A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma Recruiting NCT03016091 Phase 2 Pembrolizumab
40 Phase II Trial of Pembrolizumab in Recurrent or Residual High Grade Meningioma Recruiting NCT03279692 Phase 2 Pembrolizumab
41 A Prospective, Phase II Study of Lutetium Lu 177 Dotatate (LUTATHERA®) in Patients With Inoperable, Progressive Meningioma After External Beam Radiation Therapy Recruiting NCT04082520 Phase 2 Lutetium Lu 177 Dotatate
42 A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma Recruiting NCT02847559 Phase 2
43 A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma Recruiting NCT03604978 Phase 1, Phase 2
44 A Single Arm, Open-label, Multicenter Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma Recruiting NCT03971461 Phase 2 Lutathera
45 Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Recruiting NCT03095248 Phase 2 Selumetinib
46 Phase II, Dosimetry Guided, Peptide Receptor Radiotherapy (PRRT) Using 90Y-DOTA tyr3-Octreotide (90Y-DOTATOC) in Children and Adults With Neuroendocrine and Other Somatostatin Receptor Positive Tumors Recruiting NCT03273712 Phase 2 Amino Acids
47 Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Select Rare CNS Cancers Recruiting NCT03173950 Phase 2 Nivolumab
48 Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk Meningiomas Active, not recruiting NCT00895622 Phase 2
49 Adjuvant Postoperative High-Dose Radiotherapy for Atypical and Malignant Meningioma: a Phase-II and Observation Study Active, not recruiting NCT00626730 Phase 2
50 Feasibility and Phase II Study Using Proton Radiation For WHO Grade I-III Meningiomas and Hemangiopericytomas Active, not recruiting NCT01117844 Phase 1, Phase 2

Search NIH Clinical Center for Secretory Meningioma

Genetic Tests for Secretory Meningioma

Anatomical Context for Secretory Meningioma

MalaCards organs/tissues related to Secretory Meningioma:

40
Pituitary, Spinal Cord, Brain, Pineal, Endothelial, Thyroid, Prostate

Publications for Secretory Meningioma

Articles related to Secretory Meningioma:

(show top 50) (show all 14895)
# Title Authors PMID Year
1
[A rare case of tumor-to-tumor metastasis: secondary deposits of pulmonary adenocarcinoma in a secretory meningioma]. 61 54
12368922 2002
2
Pseudopsammomatous meningioma with elevated serum carcinoembryonic antigen: a true secretory meningioma. Case report. 61 54
1984492 1991
3
YAP1-FAM118B Fusion Defines a Rare Subset of Childhood and Young Adulthood Meningiomas. 61
33074854 2021
4
The endoscope-assisted supraorbital "keyhole" approach for anterior skull base meningiomas: an updated meta-analysis. 61
32889640 2021
5
Clinical outcome after microsurgical resection of intraventricular trigone meningiomas: a single-centre analysis of 20 years and literature overview. 61
32772161 2021
6
Meningothelial meningioma in an unusual site: Thinking out of the box. 61
33247960 2021
7
Trends in cerebrospinal fluid leak rates following the extended endoscopic endonasal approach for anterior skull base meningioma: a meta-analysis over the last 20 years. 61
33188605 2021
8
Metformin enhances anti-cancer effects of cisplatin in meningioma through AMPK-mTOR signaling pathways. 61
33575476 2021
9
Dilation of the Perioptic Subarachnoid Space Anterior to Optic Nerve Sheath Meningioma. 61
32108115 2021
10
Immunoexpression of epithelial membrane antigen in canine meningioma: Novel results for perspective considerations. 61
32875656 2021
11
FDG PET/CT of Benign Psammomatous Meningioma Effacing the Medulla. 61
33351510 2021
12
Neurosarcoidosis Masquerading as Giant Cell Arteritis With Incidental Meningioma. 61
32441899 2021
13
Metastases to meningioma-review and meta-analysis. 61
33389125 2021
14
Can Ophthalmologic Examination Predict Abducens Nerve Recovery After Endoscopic Skull Base Surgery? 61
32809233 2021
15
Convexity Meningiomas in Patients with Neurofibromatosis Type 2: Long-Term Outcomes After Gamma Knife Radiosurgery. 61
33152493 2021
16
MRI predictors for brain invasion in meningiomas. 61
32924772 2021
17
Predicting High-Value Care Outcomes Following Surgery for Skull Base Meningiomas. 61
33567369 2021
18
Treatment of WHO grade II meningiomas with stereotactic radiosurgery: identification of an optimal group for SRS using RPA. 61
33548341 2021
19
Fatty Acid-binding Protein 4 Expression in Tumor Cells as a Potential Marker for Anaplastic Meningiomas. 61
32324631 2021
20
[Sporadic meningioangiomatosis: a clinicopathological analysis]. 61
33535305 2021
21
Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. 61
33319313 2021
22
Detection of brain lesion location in MRI images using convolutional neural network and robust PCA. 61
33517817 2021
23
Role of adjuvant radiotherapy in atypical (WHO grade II) and anaplastic (WHO grade III) meningiomas: a systematic review. 61
32651886 2021
24
Spatial mechanistic modeling for prediction of the growth of asymptomatic meningiomas. 61
33348072 2021
25
Transcallosal-lateral ventricle-choroid fissure approach for excising large pineal region tumors extending into the third ventricle: experience in 15 pediatric cases. 61
32588176 2021
26
Evaluation of AQP4/TRPV4 Channel Co-expression, Microvessel Density, and its Association with Peritumoral Brain Edema in Intracranial Meningiomas. 61
33538957 2021
27
The spatial phenotype of genotypically distinct meningiomas demonstrate potential implications of the embryology of the meninges. 61
33262459 2021
28
A Deep Learning Approach for Brain Tumor Classification and Segmentation Using a Multiscale Convolutional Neural Network. 61
33540873 2021
29
Meningioangiomatosis: Multimodal Analysis and Insights From a Systematic Review. 61
33361266 2021
30
Safety and Efficacy of 980nm Diode Laser for Brain Tumor Microsurgery-A Pioneer Case Series. 61
33223128 2021
31
The Use of Augmented Reality to Improve Safety of Anterior Petrosectomy: Two-Dimensional Operative Video. 61
33220482 2021
32
AeroForm Tissue Expander: A Case of Early Accidental Inflation. 61
33538501 2021
33
Case of primary dural epithelioid angiosarcoma with review of literature and differential diagnosis. 61
33560217 2021
34
Letter to the Editor Regarding "Predictors of Nonroutine Discharge Disposition Among Parasagittal/Parafalcine Meningioma Patients". 61
33607748 2021
35
In Reply to the Letter to the Editor Regarding "Predictors of Nonroutine Discharge Disposition Among Parasagittal/Parafalcine Meningioma Patients". 61
33607749 2021
36
Letter to the Editor. Time to move beyond the Simpson scale in meningioma surgery. 61
33607616 2021
37
Growing Dural Mass That Was Not a Meningioma. 61
32644905 2021
38
Cause-Specific Survival After Meningioma Surgery: A Nationwide Population-Based Competing Risk Study. 61
33096279 2021
39
Primary intraosseous osteolytic meningioma without an evidence of soft tissue invasion. 61
33598256 2021
40
Roles for hENT1 and dCK in gemcitabine sensitivity and malignancy of meningioma. 61
33556172 2021
41
Pineal Region Meningioma in a Very Young Child. 61
33596576 2021
42
Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study. 61
33536184 2021
43
Subcutaneous seeding following surgical excision of an intracranial meningioma in a cat. 61
33588467 2021
44
Preliminary Application of Three-Dimensional Printing Technique in Preoperative Localization of Meningioma in Primary Hospitals. 61
33587526 2021
45
Integration of Different Intraoperative Ultrasound Modalities in Meningioma Surgery: A 4-Step Approach. 61
33607723 2021
46
Adjuvant radiotherapy versus observation following gross total resection for atypical meningioma: a systematic review and meta-analysis. 61
33596974 2021
47
Meningioma with ring enhancement on MRI: a rare case report. 61
33568080 2021
48
Intraparenchymal atypical meningioma in the posterior fossa: a case report and literature review. 61
33595378 2021
49
Foramen magnum meningioma with excessive calcification and no dura tail sign: A case report. 61
33578608 2021
50
Molecular changes tracking through multiscale fluorescence microscopy differentiate Meningioma grades and non-tumoral brain tissues. 61
33589651 2021

Variations for Secretory Meningioma

Expression for Secretory Meningioma

Search GEO for disease gene expression data for Secretory Meningioma.

Pathways for Secretory Meningioma

Pathways related to Secretory Meningioma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.41 VIM NF2 MUC1 KRT7

GO Terms for Secretory Meningioma

Cellular components related to Secretory Meningioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 SWI/SNF complex GO:0016514 9.16 SMARCE1 SMARCB1
2 nBAF complex GO:0071565 8.96 SMARCE1 SMARCB1
3 npBAF complex GO:0071564 8.62 SMARCE1 SMARCB1

Biological processes related to Secretory Meningioma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleosome disassembly GO:0006337 8.96 SMARCE1 SMARCB1
2 positive regulation of histone H4 acetylation GO:0090240 8.62 SMARCB1 MUC1

Sources for Secretory Meningioma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....